文献速递前列腺癌

多参数MRI-超声软件融合前列腺穿刺:机器人辅助经会阴平台的系统与靶向穿刺比较

Multiparametric MRI-ultrasonography software fusion prostate biopsy: initial results using a stereotactic robotic-assisted transperineal prostate biopsy platform comparing systematic vs targeted biopsy.
PubMed 文献 · BJU Int · 2020-09-14

该回顾性研究纳入500例mpMRI可疑病灶患者,使用机器人辅助经会阴平台行系统穿刺和MRI-经直肠超声融合靶向穿刺。在433例无既往前列腺癌诊断患者中,系统穿刺与靶向穿刺对总体及临床显著前列腺癌(ISUP GG≥2)检出率无统计学差异,但靶向穿刺采样效率更高;联合穿刺可能为检出临床显著癌的最佳方法。

要点

  • 系统穿刺与靶向穿刺对总体和临床显著前列腺癌检出率无显著差异。
  • 靶向穿刺采样效率显著高于系统穿刺。
  • 联合MRI-超声靶向穿刺与系统穿刺可能是检出临床显著癌的最佳方法。

核心结论

  • 使用机器人辅助经会阴平台时,系统穿刺与靶向穿刺对总体及临床显著前列腺癌检出率无统计学差异。
  • 靶向穿刺采样效率更高,联合靶向与系统穿刺可能是检出临床显著前列腺癌的最佳方法。

研究设计与样本

  • 回顾性分析2015年1月至2019年1月在本机构连续接受mpMRI可疑病灶、并同时行系统穿刺和MRI-经直肠超声融合靶向穿刺的患者。
  • 最终分析纳入500例患者,其中67例(13%)为主动监测中的低风险癌症患者。
  • 433例无既往前列腺癌诊断患者中,288例(67%)为初次穿刺。

主要发现

  • 433例无既往诊断患者中,248例(57%)诊断为前列腺癌,199例(46%)为临床显著前列腺癌(ISUP GG≥2)。
  • 系统穿刺与靶向穿刺总体检出率分别为51%和49%(P=0.306),临床显著癌检出率分别为40%和38%(P=0.609)。
  • 248例前列腺癌中,75%(187/248)两者均检出,14%(35/248)仅系统穿刺检出,11%(26/248)仅靶向穿刺检出。
  • 199例临床显著癌中,69%(138/199)两者均检出,17%(33/199)仅系统穿刺检出,14%(28/199)仅靶向穿刺检出。
  • 靶向穿刺对总体癌和临床显著癌的采样效率分别为23.2%和14.8%,系统穿刺分别为9.8%和5.6%(P<0.001)。

关键数值与推荐

  • 临床显著前列腺癌定义为ISUP分级分组(GG)≥2(既往称Gleason评分≥7)。
  • 按既往穿刺状态和PI-RADS v2.0评分分层后,系统与靶向穿刺检出率仍无统计学差异。

临床怎么用

  • 在机器人辅助经会阴平台上,联合MRI-超声靶向穿刺与系统穿刺可能优化临床显著前列腺癌的检出。
  • 靶向穿刺采样效率更高,但单独使用可能遗漏部分仅系统穿刺检出的癌症。

局限性

  • 回顾性研究设计。
  • 单中心、专有平台,结果外推需谨慎。
  • 纳入主动监测患者,可能影响总体检出率分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the detection rates of prostate cancer between systematic biopsy and targeted biopsy using a stereotactic robot-assisted transperineal prostate platform. MATERIALS AND METHODS: We identified consecutive patients with suspicious lesion(s) on multiparametric magnetic resonance imaging (mpMRI), who underwent both systematic and MRI-transrectal ultrasonography (US) fusion targeted biopsy using our proprietary transperineal robot-assisted prostate biopsy platform between January 2015 and January 2019 at our institution, for retrospective analysis. Comparative analysis was performed between systematic and targeted biopsy using McNemar's test, and the cohort was further stratified by prior biopsy status and Prostate Imaging Reporting and Data System (PI-RADS) v2.0 score. International Society of Urological Pathology (ISUP) grade group (GG) ≥2 cancers (previously known as Gleason grade ≥7) were considered to be clinically significant. RESULTS: A total of 500 patients were included in our final analysis, of whom 67 (13%) were patients with low-risk cancer on active surveillance. Of the 433 patients without prior diagnosis of cancer, 288 (67%) were biopsy-naïve. A total of 248 (57%) were diagnosed with prostate cancer, with 199 (46%) having clinically significant prostate cancer (ISUP GG ≥2). There were no statistically significant differences in the overall prostate cancer and clinically significant prostate cancer detection rate between systematic and targeted biopsy (51% vs 49% and 40% vs 38% respectively; P = 0.306 and P = 0.609). Of the 248 prostate cancers detected, 75% (187/248) were detected on both systematic and targeted biopsy, 14% (35/248) were detected on systematic biopsy alone and 11% (26/248) were detected on targeted biopsy alone. Of the 199 clinically significant cancers detected, 69% (138/199) were detected on both systematic and targeted biopsy, 17% (33/199) on systematic biopsy alone and 14% (28/199) on targeted biopsy alone. There were no statistically significant differences in the detection rate between systematic and targeted biopsy for both overall and clinically significant prostate cancer, even when the cohort was stratified by prior biopsy status and PI-RADS score. Targeted biopsy has greater sampling efficiency compared to systematic biopsy for both overall and clinically significant prostate cancer (23.2% vs 9.8%, P < 0.001 and 14.8% vs 5.6%, P < 0.001). CONCLUSIONS: Using our robot-assisted transperineal prostate platform, combined MRI-US targeted biopsy with concurrent systematic prostate systematic biopsy probably represents the optimal method for the detection of clinically significant prostate cancer.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Lee AYM, Yang XY, Lee HJ, et al. Multiparametric MRI-ultrasonography software fusion prostate biopsy: initial results using a stereotactic robotic-assisted transperineal prostate biopsy platform comparing systematic vs targeted biopsy. BJU Int. 2020. PMID: 32438463. doi:10.1111/bju.15118

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。